Melanoma of Unknown Primary
Associated Genetic Biomarkers
Melanoma of unknown primarys most frequently harbor alterations in BRAF, CDKN2A, TP53, ROS1, and NF1 .
BRAF Mutation, BRAF Exon 15 Mutation, BRAF Codon 600 Missense, ROS1 Mutation, and BRAF V600E are the most common alterations in melanoma of unknown primary .
There are 11 clinical trials for melanoma of unknown primary, of which 9 are open and 2 are completed or closed. Of the trials that contain melanoma of unknown primary as an inclusion criterion, 1 is phase 1 (1 open), 9 are phase 2 (7 open), and 1 is phase 3 (1 open).
BRAF is the most frequent gene inclusion criterion for melanoma of unknown primary clinical trials .
Nivolumab, binimetinib, and dabrafenib are the most common interventions in melanoma of unknown primary clinical trials.
Significant Genes in Melanoma of Unknown Primary
BRAF is altered in 48.4% of melanoma of unknown primary patients .
BRAF is an inclusion eligibility criterion in 5 clinical trials for melanoma of unknown primary, of which 3 are open and 2 are closed. Of the trials that contain BRAF status and melanoma of unknown primary as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.